Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Update

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) saw a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 6,100,000 shares, an increase of 10.3% from the September 15th total of 5,530,000 shares. Approximately 21.1% of the shares of the stock are sold short. Based on an average daily volume of 241,600 shares, the short-interest ratio is presently 25.2 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and set a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

Insider Activity

In other news, CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $24.92, for a total value of $299,040.00. Following the transaction, the chief executive officer now owns 1,063,525 shares in the company, valued at approximately $26,503,043. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CFO Benjamin Hohl sold 5,250 shares of the firm's stock in a transaction on Monday, July 29th. The stock was sold at an average price of $26.68, for a total transaction of $140,070.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Samuel Kintz sold 12,000 shares of the firm's stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $24.92, for a total value of $299,040.00. Following the sale, the chief executive officer now directly owns 1,063,525 shares in the company, valued at approximately $26,503,043. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 179,139 shares of company stock worth $4,765,385. Insiders own 29.20% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Quest Partners LLC lifted its stake in shares of Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company's stock valued at $37,000 after purchasing an additional 742 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Enliven Therapeutics by 67.0% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company's stock valued at $140,000 after purchasing an additional 3,189 shares during the period. EntryPoint Capital LLC acquired a new position in shares of Enliven Therapeutics in the 1st quarter valued at about $167,000. SG Americas Securities LLC bought a new stake in Enliven Therapeutics in the 3rd quarter valued at about $256,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Enliven Therapeutics in the 2nd quarter valued at about $322,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Stock Up 0.3 %

ELVN traded up $0.07 during midday trading on Tuesday, hitting $27.82. 119,001 shares of the company were exchanged, compared to its average volume of 262,277. The firm has a market capitalization of $1.31 billion, a P/E ratio of -14.41 and a beta of 1.10. Enliven Therapeutics has a 1-year low of $9.80 and a 1-year high of $28.62. The firm's 50 day moving average price is $23.67 and its 200-day moving average price is $22.50.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.17. On average, sell-side analysts predict that Enliven Therapeutics will post -1.98 earnings per share for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.